Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 102, Issue 2, 2008, Pages 173-188

  Berger, W E ^a   Nadel, J A ^b  

^a Allergy & Asthma Associates of Southern California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2 Adrenergic receptor agonist; Bronchodilator response; Chronic obstructive pulmonary disease; Formoterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MONTELUKAST; OXITROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AREA UNDER THE CURVE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; HUMAN; LUNG FUNCTION; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 37349061064     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.09.011     Document Type: Review

References (61)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive Summary: National Heart, Lung, and Blood Institute; 2006.
2. Tashkin D.P., Bleecker E., Braun S., et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 100 (1996) 62S-69S
3. Senn S., Richardson W.N., and Shaw M. The use of inhaled formoterol in asthma. Respir Med 85 (1991) 169-170
4. Stelmach I., Grzelewski T., Stelmach W., et al. Effect of triamcinolone acetonide, montelukast, nedocromil sodium and formoterol on eosinophil blood counts, ECP serum levels and clinical progression of asthma in children. Pol Merkur Lekarski 12 (2002) 208-213
5. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
6. FORADIL AEROLIZER (formoterol fumarate inhalation powder) [prescribing information]. In. Kenilworth, NJ: Schering Corporation, 2006.
7. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 52 (1993) 2145-2160
8. Faulds D., Hollingshead L.M., and Goa K.L. Formoterol-a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42 (1991) 115-137
9. Palmqvist M., Ibsen T., Mellen A., and Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 160 (1999) 244-249
10. van der Woude H.J., Winter T.H., and Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. Thorax 56 (2001) 529-535
11. van Veen A., Weller F.R., Wierenga E.A., Jansen H.M., and Jonkers R.E. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 16 (2003) 153-161
12. Bouros D., Kottakis J., Le Gros V., Overend T., Della Cioppa G., and Siafakas N. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV[1] reversibility. Curr Med Res Opin 20 (2004) 581-586
13. Maesen B.L., Westermann C.J., Duurkens V.A., and van den Bosch J.M. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J 13 (1999) 1103-1108
14. Kottakis J., Cioppa G.D., Creemers J., et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 9 (2002) 107-115
15. Celik G., Kayacan O., Beder S., and Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. Respiration 66 (1999) 434-439
16. Cazzola M., Grella E., Matera M.G., Mazzarella G., and Marsico S.A. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. Pulm Pharmacol Ther 15 (2002) 97-102
17. Cazzola M., Centanni S., Regorda C., et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther 14 (2001) 41-45
18. Benhamou D., Cuvelier A., Muir J.F., et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 95 (2001) 817-821
19. Cazzola M., Santangelo G., Piccolo A., et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 7 (1994) 103-107
20. Sichletidis L., Kottakis J., Marcou S., Constantinidis T.C., and Antoniades A. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 53 (1999) 185-188
21. Cazzola M., Di Marco F., Santus P., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17 (2004) 35-39
22. Di Marco F., Milic-Emili J., Boveri B., et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 21 (2003) 86-94
23. Chhabra S.K., Vijayan V.K., and Vasu T. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 48 (2006) 97-102
24. Richter K., Stenglein S., Mucke M., et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 73 (2006) 414-419
25. Cazzola M., Matera M.G., Santangelo G., Vinciguerra A., Rossi F., and D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89 (1995) 357-362
26. Aalbers R., Ayres J., Backer V., et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19 (2002) 936-943
27. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
28. Rossi A., Kristufek P., Levine B.E., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121 (2002) 1058-1069
29. Campbell M., Eliraz A., Johansson G., et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 99 (2005) 1511-1520
30. Vervloet D., Ekstrom T., Pela R., et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 92 (1998) 836-842
31. van Noord J.A., Aumann J.L., Janssens E., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
32. D'Urzo A.D., De Salvo M.C., Ramirez-Rivera A., et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 119 (2001) 1347-1356
33. van Noord J.A., Aumann J.L., Janssens E., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129 (2006) 509-517
34. Di Marco F., Verga M., Santus P., Morelli N., Cazzola M., and Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 100 (2006) 1925-1932
35. Celik P., Sakar A., Havlucu Y., Yuksel H., Turkdogan P., and Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 99 (2005) 444-450
36. Yildiz F., Basyigit I., Yildirim E., Boyaci H., and Ilgazli A. Different bronchodilator combinations have similar effects on health status in COPD. Pulm Pharmacol Ther 19 (2006) 101-106
37. Zheng J.P., Kang J., Cai B.Q., et al. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 29 (2006) 363-367
38. Cazzola M., Santus P., Di Marco F., et al. Bronchodilator effect of an inhaled combination therapy with salmeterol+fluticasone and formoterol+budesonide in patients with COPD. Respir Med 97 (2003) 453-457
39. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
40. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., and Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-919
41. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol 110 (2002) S322-S328
42. Cazzola M., Imperatore F., Salzillo A., et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114 (1998) 411-415
43. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
44. SEREVENT DISKUS (salmeterol xinafoate inhalation powder) [prescribing information]. In. Research Triangle Park, NC: GlaxoSmithKline, 2004.
45. Kemp J.P., Bierman C.W., and Cocchetto D.M. Dose-response study of inhaled salmeterol in asthmatic patients with 24-h spirometry and Holter monitoring. Ann Allergy 70 (1993) 316-322
46. Malolepszy J., Boszormenyi Nagy G., Selroos O., Larsso P., and Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 18 (2001) 928-934
47. Lotvall J., Lunde H., and Svedmyr N. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. Can Respir J 5 (1998) 191-194
48. Bronsky E.A., Kemp J.P., Orgel H.A., et al. A 1-week dose-ranging study of inhaled salmeterol in patients with asthma. Chest 105 (1994) 1032-1037
49. Bennett J.A., and Tattersfield A.E. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 52 (1997) 458-464
50. Maesen F.P., Costongs R., Smeets J.J., Brombacher P.J., and Zweers P.G. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 99 (1991) 1367-1373
51. Cheung D., Timmers M.C., Zwinderman A.H., Bel E.H., Dijkman J.H., and Sterk P.J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327 (1992) 1198-1203
52. Grootendorst D.C., Sterk P.J., and Heijerman H.G. Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma. Eur Respir J 17 (2001) 374-379
53. Verberne A.A., Frost C., Roorda R.J., van der Laag H., and Kerrebijn K.F. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 156 (1997) 688-695
54. Goldkorn A., Diotto P., Burgess C., et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 9 (2004) 102-108
55. Cazzola M., Di Perna F., Noschese P., et al. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 11 (1998) 1337-1341
56. Cazzola M., D'Amato M., Califano C., et al. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 24 (2002) 595-604
57. Cazzola M., Matera M.G., D'Amato M., et al. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Pulm Pharmacol Ther 16 (2003) 105-109
58. Cazzola M., Santus P., Matera M.G., et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 97 (2003) 458-462
59. Cazzola M., Di Perna F., D'Amato M., Califano C., Matera M.G., and D'Amato G. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 95 (2001) 917-921
60. Cazzola M., Santus P., Di Marco F., et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 17 (2004) 121-125
61. Rosenkranz B., Rouzier R., Kruse M., et al. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med 100 (2006) 666-672